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In 2015 South Africa established a national cryptococcal antigenemia (CrAg) screening pol-
icy targeted at HIV-infected patients with CD4+ T-lymphocyte (CD4) counts <100 cells/ μl
who are not yet on antiretroviral treatment (ART). Two screening strategies are included in
national guidelines: reflex screening, where a CrAg test is performed on remnant blood
samples from CD4 testing; and provider-initiated screening, where providers order a CrAg
test after a patient returns for CD4 test results. The objective of this study was to compare
costs and effectiveness of these two screening strategies.
Methods
We developed a decision analytic model to compare reflex and provider-initiated screening
in terms of programmatic and health outcomes (number screened, number identified for pre-
emptive treatment, lives saved, and discounted years of life saved) and screening and treat-
ment costs (2015 USD). We estimated a base case with prevalence and other parameters
based on data collected during CrAg screening pilot projects integrated into routine HIV
care in Gauteng, Free State, and Western Cape Provinces. We conducted sensitivity analy-
ses to explore how results change with underlying parameter assumptions.
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Results
In the base case, for each 100,000 CD4 tests, the reflex strategy compared to the provider-
initiated strategy has higher screening costs ($37,536 higher) but lower treatment costs
($55,165 lower), so overall costs of screening and treatment are $17,629 less with the reflex
strategy. The reflex strategy saves more lives (30 lives, 647 additional years of life saved).
Sensitivity analyses suggest that reflex screening dominates provider-initiated screening
(lower total costs and more lives saved) or saves additional lives for small additional costs
(< $125 per life year) across a wide range of conditions (CrAg prevalence, patient and pro-
vider behavior, patient survival without treatment, and effectiveness of preemptive flucona-
zole treatment).
Conclusions
In countries with substantial numbers of people with untreated, advanced HIV disease such
as South Africa, CrAg screening before initiation of ART has the potential to reduce crypto-
coccal meningitis and save lives. Reflex screening compared to provider-initiated screening
saves more lives and is likely to be cost saving or have low additional costs per additional
year of life saved.
Background
Cryptococcal meningitis (CM) is a leading cause of death among HIV-infected patients with
low CD4+ T-lymphocyte (CD4) counts. Further, patients with undiagnosed cryptococcal dis-
ease at time of antiretroviral treatment (ART) initiation are at high risk for death from immune
reconstitution inflammatory syndrome (IRIS) [1–3]. Cryptococcal antigenemia (CrAg) can be
diagnosed weeks before CM onset with near-perfect sensitivity and specificity [4, 5], and treat-
ment of CrAg positive patients who do not already have CM with high-dose fluconazole
reduces both progression to CM and the risks of death from cryptococcal IRIS [6–8]. The
median time between becoming CrAg positive and developing CM is three weeks [5], making
it imperative to identify and treat CrAg positive patients quickly. Previous research suggests
that, compared to no screening, a CrAg screen-and-treat approach prior to the initiation of
ART among patients with low CD4 counts is cost effective [9–12].
As of 2015, the South African government recommended that “HIV-positive adults with a
CD4 count<100 cells/μl should be screened for cryptococcal disease before ART is started”
[13]. The relevant issue is how to most efficiently integrate CrAg screening into a large HIV
treatment program. Two CrAg screening strategies are currently included in South African
guidelines: reflex and provider-initiated screening (see page 99 in [13]). With reflex screening,
a single patient blood sample is drawn at the time of HIV diagnosis for a baseline CD4 count,
the current standard of care. The lab tests all remnant samples with CD4 counts< 100 cells/μl
for CrAg (a qualitative result showing positive or negative), regardless of patient's ART or prior
CM status, because both are unknown to lab staff. Finally, providers (generally nurses), review
both CD4 and CrAg results when patients return for their second visit. With provider-initiated
screening, a blood sample is drawn at the time of HIV diagnosis for an initial CD4 test, fol-
lowed by review of CD4 results during a second patient visit to the clinic. At this second visit,
providers must determine if a CrAg test is indicated (i.e. CD4 count< 100 cells/μl, ART naïve,
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and no prior CM), draw a second blood sample, and send it to the lab. The patient must then
return for a third visit to review the results of the CrAg test.
In this paper, we present a decision-analytic model to compare reflex and provider-initiated
CrAg screening strategies based on costs (2015 USD), disaggregated into screening, preemptive
treatment to avoid hospitalization, hospital, and post-hospital costs, and health outcomes (lives
saved and years of life saved using a 3% discount rate). Although prior research has shown that
CrAg screening prior to ART initiation is cost effective, alternative strategies for CrAg screen-
ing have not been compared systematically. Thus, the focus here is on the difference in costs
between the two strategies, the difference in health outcomes achieved, and the incremental
cost effectiveness of reflex compared to provider-initiated screening.
Of particular interest is the impact of provider and patient adherence to the different strat-
egy protocols. The provider-initiated strategy places responsibility on providers to assess cor-
rectly patient eligibility for CrAg screening, while the reflex strategy does not. Both strategies
require patients to return for a second visit. High rates of loss-to-follow-up after HIV diagnosis
are well documented in South Africa and elsewhere [14–18], which affects both screening strat-
egies. The provider-initiated policy additionally requires a patient to return for a third visit to
obtain CrAg results, which creates another opportunity for patients to be missed by this screen-
ing strategy. In addition, because a third visit would be required prior to ART initiation with a
provider-initiated policy, ART initiation could be delayed for the majority of targeted patients
(pre-ART, CD4 count< 100 cells/μl) who will screen CrAg negative. While not discussed fur-
ther in this paper, potential ethical differences between the two strategies could also be consid-
ered, since patients with CD4 counts< 100 cells/μl by definition have advanced HIV disease,
and provider-initiated screening involves more delay in treatment, either initiation of ART for
those CrAg negative or fluconazole for those CrAg positive.
We parameterize the model for a base case using program evaluation data observed during
large- scale pilot CrAg screening programs in Gauteng, Free State, andWestern Cape Provinces
[19]. Additional parameters related to CD4 testing, patient behavior, and costs of CrAg screen-
ing are drawn from existing literature and information from the National Health Laboratory
Service (NHLS). For certain parameters, good data do not exist. Therefore, we complete a series
of sensitivity analyses to consider implications of varying key parameters, such as CrAg preva-
lence and adherence to screening guidelines (e.g., patients returning for CD4 results, providers
ordering CrAg tests when indicated by guidelines).
Methods
Reflex and provider-initiated strategies were modeled in two stages: the screening stage and the
treatment stage. The screening stage identifies two main categories of patients for the treatment
stage: (i) incident CrAg positive patients identified for preemptive treatment; and (ii) incident
CrAg positive patients missed by the screening program who also develop CM (discussed in
more detail below).
In the treatment stage, costs include outpatient fluconazole treatment for patients identified
for preemptive treatment in the screening stage. Treatment costs also include hospitalization and
post-hospital treatment for patients who develop CM, which includes some patients missed by
the screening program and patients identified for preemptive treatment who may still develop
CM. A patient’s outcome in the screening stage determines where they enter the treatment stage.
The structure of the treatment cost module is the same for both strategies; only the starting num-
bers of patients in each arm of the model differ (based on the results of the screening program).
A key starting point for this analysis is CrAg prevalence in the target population at the time
of CD4 count testing. While CrAg prevalence in some populations has been reported in many
Cost Effectiveness of Reflex and Provider-Initiated CrAg Screening
PLOS ONE | DOI:10.1371/journal.pone.0158986 July 8, 2016 3 / 23
prior studies [6, 7, 9, 20, 21], the distribution of CrAg positive patients not yet on ART with
CD4 counts<100 cells/ μl will include incident cases as well as those with prior, treated CM.
Among the CrAg positive incident group (the target group for preemptive treatment), some
will have low fungal burden at time of screening (and no evidence of cerebrospinal fluid (CSF)
disease) and be good candidates for preemptive fluconazole treatment. Others will have a high
fungal burden with likely meningitis already at the time of screening and fare poorly on pre-
emptive treatment. For the base case, CrAg prevalence and provider and patient adherence
parameters were based on data reported from an evaluation study of CrAg screening programs
in South Africa [19, 22].
The remainder of this section works through the screening and treatment cost modules.
Tables 1 and 2 and S1 Appendix provide all information not included in screening and treat-
ment flowcharts discussed below. Excel was used for all calculations.
Reflex Screening
The screening stage for the reflex strategy is described in Figs 1–3. Parameter assumptions for
the base case scenario are included in parentheses in these figures, with additional details pro-
vided in Table 1.
Under the reflex strategy, 10% of blood samples have a CD4 count< 100 cells/uL; 95% of
these are tested for CrAg, with the remaining 5% not tested due to non-adherence to guidelines
by lab personnel (Fig 1). In 2014, the NHLS completed about 3.9 million CD4 count tests, and
9.3% (362,000) specimens had a CD4 count< 100 cells/μl [23].
Table 1. Distribution of CrAg status in population.
Prevalence based on test results
Proportion CrAg- 0.954
Proportion prior CM 0.016
Proportion incident CrAg+ 0.030
Among incident CrAg+
proportion CSF+ at time of screening 0.330
proportion CSF- at time of screening 0.670
Among incident CrAg+ but CSF-
proportion develops CM if not initiated on ART 0.900
proportion develops CM if initiated on ART 0.660
doi:10.1371/journal.pone.0158986.t001
Table 2. Basic unit costs andmodel assumptions.
Year for analysis 2015
Types of costs Rand USD Notes
Unit cost of CrAg test (reflex) 75.00 4.95 Rand.
Unit cost of CrAg test (provider-initiated) 93.75 6.19 Rand (25% above reflex, as explained in text).
Unit cost (200 mg fluconazole tablet) 0.86 0.06 See S1 Appendix.
Preemptive fluconazole treatment (outpatient) 455.72 30.09 See S1 Appendix.
Hospitalization and treatment for cryptococcal meningitis 29535.00 1,950.10 See S1 Appendix.
Post-hospital maintenance fluconazole treatment (outpatient) 405.84 26.80 See S1 Appendix.
Other
Life expectancy at death (death at age 35–39) 32.6 World Health Organization’s Global Health Observatory
Disability adjusted life years lost per death (3% discount rate) 21.6 Calculated by authors using discrete time approach [24].
2015 exchange rate (ZAR/USD) 15.15 Oanda.com (December 14, 2014–2015)
doi:10.1371/journal.pone.0158986.t002
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Among the 5% of samples that are not tested, the base case assumption is that 80% are from
patients who are pre-ART (and 20% are from patients already on ART). This is based on CD4
results from eight Right to Care-supported public clinics in Gauteng Province from 2013.
Although the South African CrAg screening guidelines specifically target patients who are not
yet on ART, reflex lab screening procedures do not identify patients with low CD4 counts who
Fig 1. Reflex screening flowchart (Panel 1a).
doi:10.1371/journal.pone.0158986.g001
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are on ART. Since patients on ART are not the intended targets for CrAg screening (Fig 1, arm
1), they are excluded from further analysis in the model (i.e., they incur screening costs but do
not contribute to estimates of health outcomes or treatment costs).
Among those not screened, we use existing program data to estimate that 95.4% are CrAg
negative (Fig 1, arm 3), 1.6% are patients with prior CM (arm 2), and 3.0% are incident CrAg
positive cases. The screening program misses these incident CrAg positive patients.
Among these CrAg positive patients who are missed by the screening program, because
they were not screened, the base case assumption in Table 1 is that 33% have a high fungal bur-
den, are already CSF positive at time of screening, and will develop CM (Fig 1, arm 4). Among
the 67% with low fungal burden and CSF negative at time of screening, we assume that 60% ini-
tiate ART quickly and 40% do not. Among those who initiate ART when CSF negative, the
base assumption is that 66% develop CM in the absence of fungal treatment. Of those who do
not initiate ART when CSF negative, 90% will develop CM. Combining the CSF negative
patients who do and do not initiate ART, 50.7% of CrAg positive patients missed by the screen-
ing program will develop CM (Fig 1, arm 5). The remaining 16.3% of CrAg positive individuals
missed do not develop CM (Fig 1, arm 6).
Actual data on the proportion of CrAg positive individuals, with low CD4 counts and CSF
negative at the time of CD4 testing, who then develop CM does not exist for a large population
of HIV-infected patients (whether there is rapid initiation of ART or not). The implications of
these assumptions are explored further through sensitivity analysis following the presentation
of main results.
Among the 95% of reflex samples tested for CrAg (Fig 2), 80% are assumed to be from
patients who are pre-ART. The question is: do these patients return ‘quickly enough’ to poten-
tially benefit from initiation of preemptive treatment? The definition of ‘quickly enough’ is
intended to recognize that CrAg positive patients need to be identified early enough for pre-
emptive treatment to be successful (so CM and hospitalization is avoided). This time period is
not well defined in the literature and varies depending on CrAg titer at the time of the CD4
count/CrAg tests (which is unknown with the qualitative CrAg test in use in South Africa).
South African CrAg program evaluation data suggest that, of the 80% of patients who returned
for CD4 results after HIV testing, 75% returned within 28 days. Thus, our base assumption is
that 60% (75%80%) return quickly enough, defined as 28 days, and 40% do not. These
numbers are also consistent with prior literature evaluating losses to follow up after initiating
CD4 testing [14, 18].
For the base case (Fig 2), among the 40% of patients who do not return quickly enough, 3%
are CrAg positive and missed by the screening program. Because they do not return for ‘quickly
enough’ for CD4 results, we therefore assume they do not initiate ART quickly enough for
ART-induced immune recovery alone to reduce their risk of progression to CM. As in Panel
1a, we assumed that 33% are CSF positive at the time of screening and 67% are CSF negative.
We assume that 90% of missed patients who are CSF negative will develop CM (so
0.900.67 = 60.3% of all CrAg positive patients who did not return for their CD4 result will
develop CM).
Among the 60% of pre-ART patients who return ‘quickly enough’ to the clinic for a second
visit, 95.4% are CrAg negative, 1.6% are positive and have had prior CM, and 3% are incident
CrAg positive patients (Fig 3). The incident CrAg positive patients (Fig 3, arm 14) are the
intended targets of the screening program actually identified by the screening program; those
with prior CM (Fig 3, arm 13) happen to be screened due to the reflex policy and incur screen-
ing costs (but have no further health outcomes or treatment costs in this analysis).
Based on the model outlined in Figs 1–3, the reflex screening program incurs screening
costs and identifies two main categories of patients for the treatment cost module: (i) patients
Cost Effectiveness of Reflex and Provider-Initiated CrAg Screening
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Fig 2. Reflex screening flowchart (Panel 1b).
doi:10.1371/journal.pone.0158986.g002
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missed by the screening program who develop CM (arms 4, 5, 10, 11); and (ii) patients identi-
fied for preemptive treatment (arm 14). The cost of screening is simply the unit cost of a CrAg
test, with a base case of $4.95 per test (year of analysis is 2015, see Table 2).
Provider-initiated Screening
The logic of the provider-initiated screening module, presented in Figs 4–7, is similar to the
reflex screening analysis but with a few key adjustments due to the structure of provider-initi-
ated screening.
The first key difference between the two strategies is that, with provider-initiated screening,
patients need to return ‘quickly enough’ for their CD4 results, and also then return ‘quickly
enough’ to collect CrAg results (two return visits to complete CrAg screening are needed with
the provider-initiated policy rather than the one needed for the reflex policy). In Fig 4, as with
the reflex policy, 10% of blood samples sent for CD4 testing have a CD4 count< 100 cells/μl,
and 80% of these patients are not yet on ART. In Fig 4, the base case assumes that 48% of
patients return quickly enough for CD4 results, so that they could return again quickly enough
for CrAg results, with both visits completed within a total of 28 days (to be consistent with the
reflex policy). For reference, 48% is consistent with the assumption that 60% of patients return
within 28 days (as with the reflex policy), and 80% of these patients return quickly enough
(60%80% = 48%) to be able to collect CrAg test results within 28 days.
A second key difference between the two screening strategies is that provider-initiated
screening allows clinicians to target CrAg screening to the intended group of patients: those
who are pre-ART and with CD4 count< 100 cells/μl. In Fig 5, only these patients are screened;
there are no costs associated with screening patients already on ART. In theory, providers
would discuss CrAg screening with patients, and any patient with a known history of prior CM
Fig 3. Reflex screening flowchart (Panel 1c).
doi:10.1371/journal.pone.0158986.g003
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would not be screened for CrAg. However, based on existing program experience, providers
may still request the test and, therefore, some of those screened for CrAg will be patients with
prior CM.
A third key difference between the two strategies is provider adherence to screening guide-
lines. With the reflex policy, 95% of all patients who should be screened for CrAg are screened
(in addition to patients who are not the target of the screening program), and CD4 count and
Fig 4. Provider-initiated screening flowchart (Panel 2a).
doi:10.1371/journal.pone.0158986.g004
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CrAg results are available to the clinician simultaneously. With the provider-initiated policy,
which depends on provider decision-making, such high levels of adherence to guidelines can-
not be assumed. Experience from the Western Cape Province, which implemented the pro-
vider-initiated policy, showed low adherence to guidelines, with some modest improvement
over time (< 35% across all time periods) [25]. Assuming that some improvement could be
obtained over time with better training, the base case assumption is that providers request the
CrAg test on 40% of patients who should receive the test; that is, 40% of the pre-ART patients
with CD4 count< 100 cells/μl who return quickly enough to learn their CD4 results receive
CrAg testing by providers.
Returning to Fig 4, among the 52% of patients who do not return to the clinic to learn their
CD4 test results, we again assume that 3.0% are incident CrAg positive, 1.6% have had prior
CM, and 95.4% are CrAg negative. As in Figs 1–3 for reflex screening, 33% of the incident
CrAg positives patients will already be CSF positive and develop CM (Fig 4, arm 4). Among the
67% who are CSF negative, since these patients are also unlikely to initiate ART quickly because
they did not return for CD4 results, 90% of these patients are assumed to develop CM.
Of the 48% of patients with CD4 count< 100 cells/μl who return for CD4 results, providers
request CrAg tests on 40% of these patients. For the remaining 60% not tested for CrAg, again
3% are incident CrAg positive (Fig 5). As with reflex screening, 33% of the incident CrAg posi-
tives patients will also already be CSF positive and develop CM. Among the 67% who are CSF
negative, since these patients returned for CD4 results (but then did not receive a CrAg test),
some patients initiate ART and some do not, so the proportions in Fig 5 (arms 9–11) are identi-
cal to the proportions in Fig 1 (arms 4–6).
The patients actually screened for CrAg need to return quickly enough (their third visit to
the clinic within 28 days) to obtain their CrAg results. Data are currently not available to be
able to provide a reasonable estimate for this parameter. As a base case, we assume that 80% of
these patients return within 28 days, and 20% do not. A high proportion, such as 80%, seems
plausible because these are patients who already returned quickly for CD4 results, know their
low CD4 results, and are likely to be motivated to return again quickly.
Among patients tested for CrAg who do not return quickly enough (20% of those tested),
3.0% are incident CrAg positive with the same structure of outcomes (missed and developed
CM) as in Fig 6 as in Fig 4. For the 80% of patients who do return quickly enough for their
CrAg results with provider-initiated screening (Fig 7), they have the same overall experience as
those under the reflex strategy: 3.0% are incident CrAg positive, 95.4% are CrAg negative, and
1.6% have had prior CM.
Based on the model outlined in Figs 4–7, the provider-initiated strategy identifies two main
categories of patients for the treatment cost module: (i) patients missed by the screening pro-
gram who develop CM (arms 4, 5, 9, 10, 14, 15); and (ii) patients identified for preemptive
treatment (arm 18). The cost of screening is again simply the unit cost of a CrAg test completed
as a stand-alone test, which is discussed in more detail in the section below on unit costs.
Far fewer patients will be screened for CrAg with the provider-initiated policy in part
because screening is avoided for patients already on ART. In addition, patients who should be
screened are not because they do not return for CD4 results and providers do not order the
CrAg test.
Treatment
The treatment stage is presented in Figs 8 and 9. Additional basic information on treatment
costs is provided in Table 2 (and S1 Appendix). The treatment module is organized into two
main treatment arms, one for each of the categories of patients identified in the screening
Cost Effectiveness of Reflex and Provider-Initiated CrAg Screening
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modules: (i) CrAg positive patientsmissed in the screening stage who develop CM (Fig 8); and
(ii) CrAg positive patients identified for preemptive fluconazole treatment (Fig 9). The struc-
ture of the treatment cost module is the same regardless of screening strategy, but the starting
numbers of patients in each category (incurring treatment costs and health outcomes) are
derived from the screening strategy.
Care for CrAg positive patients missed during screening who develop CM is described in
Fig 8. Among these patients who develop CM, 80% are hospitalized with CM, and 68% survive
hospitalization. Among those who survive hospitalization, 75% will be successful on mainte-
nance fluconazole and 25% will fail maintenance treatment and have CM relapse. The 20%
with CM not hospitalized die at home.
Fig 5. Provider-initiated screening flowchart (Panel 2b).
doi:10.1371/journal.pone.0158986.g005
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The treatment cost module for CrAg positive patients identified for preemptive treatment is
described in Fig 9. While preemptive treatment with fluconazole is indicated for all of these
patients, 10% do not receive preemptive treatment, whether due to failure to initiate flucona-
zole by providers, pharmacy stock-outs, or patient behavior.
Among those that do not receive preemptive treatment, most will develop CM. Using the
same logic as in Fig 1 (arms 4–6), the base case assumption is that 16.3% will never develop
CM while 83.7% develop CM (accounting for those already CSF positive and those who are
CSF negative but develop CM regardless of ART status). Of the 83.7% who develop CM, we
assume that 80% will eventually be hospitalized for CM, with 68% surviving hospitalization
and 32% dying in the hospital [26]. The 20% with CM not hospitalized also die. Among those
who survive hospitalization, 75% are assumed to be successful on post-hospitalization
Fig 6. Provider-initiated screening flowchart (Panel 2c).
doi:10.1371/journal.pone.0158986.g006
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maintenance fluconazole treatment, while the remaining 25% will fail maintenance treatment
and have a relapse of CM. Although good data do not exist on some of these parameters,
because the focus here is on the comparison of the two models, changes in these assumptions
(e.g., 80% hospitalized to 50% or 100%) will affect treatment costs and outcomes for both strat-
egies in the same way (hospital costs increase or decrease for both strategies, lives saved
increase or decrease).
For this analysis, a relapse of CM is an endpoint, and we do not include additional treatment
costs for these patients or include them in the outcome estimates (e.g. lives saved). A small
number of patients have this endpoint, so the additional treatment costs and health outcomes
are essentially irrelevant for a policy comparison.
Most patients identified for preemptive treatment initiate treatment (90%). Current guidelines
in South Africa for preemptive care of identified CrAg positive patients are 800mg of fluconazole
for 2 weeks prior to the initiation of ART, followed by initiation of ART and continuation of
daily fluconazole, 400mg for 8 weeks and then 200mg daily for at least 1 year until CD4 counts
are> 200 cells/μl.[13, 27] The details vary slightly depending on if the patient has symptoms rel-
evant to CM and if the patient receives a lumbar puncture for further diagnosis.
Some incident CrAg positive patients will also receive a lumbar puncture to assess CSF sta-
tus, whether symptomatic or asymptomatic, after receiving their CrAg test results, at the same
visit or a future visit perhaps to another facility.[28] The costs of such lumbar punctures are
excluded from the treatment model in large part because the additional cost of a lumbar punc-
ture is small (see, e.g., [12]) and the result is basically the same (they are CSF positive at the
time of initiating preemptive treatment).
Fig 7. Provider-initiated screening flowchart (Panel 2d).
doi:10.1371/journal.pone.0158986.g007
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Among the patients initiated on preemptive fluconazole, some will be treated successfully
and some will fail on preemptive treatment and develop CM (or be diagnosed as CSF positive
after a lumbar puncture). Among those initiated on preemptive treatment, an estimated 39.7%
will fail preemptive treatment, which combines the 33% of patients already CSF positive at
time of preemptive treatment initiation as well as a small share (10%) of those CSF negative.
The remaining 60.3% initiated on preemptive treatment will not develop CM. Of the patients
who develop CM after initiating preemptive treatment, 80% are hospitalized, of whom 68%
survive. Of the patients who survive hospitalization, 75% are successful on maintenance flucon-
azole. The 20% of patients who fail preemptive treatment, but are never hospitalized and die at
home, may have failed on preemptive fluconazole due to being CSF positive at time of flucona-
zole initiation of lack of patient adherence to fluconazole.
Fig 8. Treatment model flowchart (Panel 3a).
doi:10.1371/journal.pone.0158986.g008
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Costs and health outcomes
Parameter assumptions related to the costs of screening and treatment as well as health out-
comes are presented in Table 2 (and S1 Appendix). Based on existing analysis by the NHLS,
$4.95 is a best estimate of the average cost of a reflex CrAg test after CD4 testing (across labs of
varying daily sample volumes).
Fig 9. Treatment model flowchart (Panel 3b).
doi:10.1371/journal.pone.0158986.g009
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Under the provider-initiated strategy, the CrAg test is completed as a separate test, which
requires additional provider time, an additional blood draw, additional transport to lab, addi-
tional data entry into electronic data systems, etc. Thus, the unit cost for one CrAg test will be
higher with the provider-initiated policy. As a base case, we assume a 25% cost differential
between the two strategies for a cost of $6.19 for provider initiated CrAg testing.
Patients started on preemptive fluconazole treatment, and who fully adhere to a one-year
treatment course, require 533 tablets (200mg each). The cost per 200mg tablet is $0.056, for a
total cost of $30.09. The price per tablet is based on the most recent negotiated fluconazole ten-
der in South Africa at the time of this analysis (2015). The cost in USD looks especially low
because of the very weak exchange rate in 2015 (ZAR/$15). Not all patients will complete the
full year of preemptive treatment. For the base case, partial adherence is defined as taking 66%
of the total prescribed annual amount (so 355 200mg tablets at a total cost of $19.86).
For patients with CM successfully treated in the hospital (with 14 days of amphotericin B and
related services and hotel costs), we use recently published data on hospitalization costs per day
in South Africa to estimate the costs of a full 15-day hospital stay at $1950 ($130 per day). Com-
pared to basic hotel costs, the costs of services provided in the hospital (amphotericin B, lumbar
punctures, intravenous saline, etc.) are relatively minor. As an alternative, hospital costs would be
slightly lower if we used the detailed information on hospital services and costs reported in Jarvis
et al. (see [12]), and then inflated their 2010 values up to 2015 (see S1 Appendix for details).
Those who do not survive the hospital are assumed to require six hospitalized days on aver-
age [28], at a total cost of $780. Finally, most patients who survive hospitalization for CM will
be started on maintenance fluconazole treatment. Those that fully adhere throughout the one-
year treatment course receive 477200mg tablets, for a total cost of $26.9. Partial adherence for
maintenance fluconazole is defined as 75% of full adherence, so these patients receive 358200
mg tablets at a total cost of $20.2.
Patients can have three primary outcomes at the end of the treatment module: survived,
died, unknown. In the treatment cost module, patients in Fig 8 (arm 4) and Fig 9 (arms 9 and
14) are classified as unknown. Some will die without returning to a hospital. Some of these
patients may live long enough to return to a hospital for additional care (and perhaps not die).
While additional arms could be developed to allow for such details, the extra complexity pro-
vides little additional information for comparing the two policies (overall total costs would
increase by a minor amount and deaths would decrease by a minor amount).
For comparing the two screening strategies, health outcomes are based on known lives
saved from screening and treatment as well as patients missed by the screening program who
do not develop CM. When comparing the two strategies, the difference in this outcome is the
additional lives saved from reflex compared to provider-initiated screening. For patients who
die from CM, the base case assumption is that the average age of death is between 35–39 years.
For this age range, average life expectancy is 32.6 additional years (data from the World Health
Organization’s Global Health Observatory). With a 3% discount rate and 32.6 years of life lost
from a death, 21.6 discounted years of life are lost per death, or conversely 21.6 years of life are
saved per avoided death.
Patients with CM experience serious symptoms and disability whether receiving treatment
or not. Thus, in general, the period of time lived disabled due to CM disease prior to and during
treatment could be added into the analysis (with disability adjusted life years (DALYs) lost as
the combined health outcome). However, the time period for disability for these patients is
fairly short (they either respond to treatment or die within one year), so the “years lived dis-
abled” component of DALYs before completion of treatment will be minor for CM compared
to the “years of life lost” component (this disability component would add less than 1 to the
21.6 years of life lost already estimated).
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In addition, patients who survive their hospital stay and complete the post-hospital flucona-
zole treatment could have long-term impairment from CM despite surviving. For example, dis-
ability weights for meningitis-related conditions used previously in the Global Burden of
Disease estimates are, for example, deafness = 0.229; intellectual impairment = 0.456; and
motor deficit = 0.380.[29] Such long-term impacts will reduce the estimated health benefits
from successful CM treatment to some degree, but are excluded for the base case analysis. The
implications of including such long-term disability into the analysis are discussed as part of the
sensitivity analysis section following the presentation of the base-care results.
Results
Base case model assumptions
In the base case population of 100,000 patients who receive a CD4 test, 8,000 have a CD4 count
<100 cells/μl and are not yet on ART. The goal of screening is to identify the 240 patients out
of 8,000 who are not yet on ART, with incident CrAg (no prior CM). In the absence of a screen-
ing program, all of these patients are missed. In the presence of a screening program, with the
base case assumptions and analysis presented in Figs 1–9 and Tables 1, 2 and 3 summarizes
screening results (categories of patients identified by the screening strategies) and Table 4 sum-
marizes results related to costs of screening and treatment and health outcomes achieved.
Costs and outcomes of screening
From Table 3, the reflex policy correctly identifies substantially more patients who are the tar-
get of the screening program than the provider-initiated approach (137 compared to 37 out of
the 240 patients, respectively). An important share of patients missed by the screening pro-
gram, as well as those identified for preemptive treatment, are already CSF positive, although
this information is not known at the time of screening. We consider these patients missed by
the screening program, but perhaps a better interpretation is that these patients presented for
HIV care too late in their disease progression to benefit from preemptive treatment.
From Table 4, 9,500 patients are screened with the reflex policy for a total cost of $47,044.
With the provider-initiated policy, 1,536 patients are screened for a cost of $9,508. While the
reflex policy screens more patients that are not the target of the policy, the provider-initiated
policy misses a large share of the target patients because a large share of patients do not return
for CD4 results, and then providers fail to order CrAg testing for a large share who do return.
Costs and outcomes of treatment
In the base case summarized in Table 4, reflex screening dominates provider-initiated screen-
ing. The cost of screening is substantially higher with the reflex policy compared to the pro-
vider-initiated policy ($37,536 more), but the cost of treatment (preemptive, hospitalization,
Table 3. Outcomes from screening modules for 100,000 patients screened for cryptococcal antigene-
mia (CrAg).
RP PIP
Total Screened 9500 1536
Identified for preemptive treatment 136.8 36.9
Missed and develops CM 95.1 189.5
Missed but does not develop CM 8.1 13.6
Total incident CrAg+ 240.0 240.0
doi:10.1371/journal.pone.0158986.t003
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and post-hospital maintenance) is substantially lower ($55,165 less), so that the total cost of
screening and treatment per 100,000 CD4 tests for the reflex strategy is $17,629 less than for
the provider-initiated strategy.
In terms of health outcomes, the reflex policy is also estimated to save an additional 30 lives
per 100,000 CD4 tests (647 additional years of life saved). Note that these are estimates of addi-
tional patients “known” to be living at the end of the treatment stage; any patients in the treat-
ment arms with indeterminate final health outcomes (CM relapse) are not included in this
estimate, but their treatment costs are included. For reference, there are 21 patients in the reflex
policy treatment module and 28 patients in the provider-initiated treatment module with this
indeterminate health outcome (Fig 8, arm 4 and Fig 9, arms 9 and 14).
Table 5 provides additional information on the cost of treatment, disaggregated into pre-
emptive fluconazole treatment, hospitalization, and post-hospital maintenance treatment. For
both policies, the majority of treatment costs are associated with hospital-based treatment for
CM. The reflex policy is able to identify more patients for preemptive treatment in the base
case, so that cases of CM are avoided. However, a substantial number of patients are missed
and develop CM with both policies as described above, so that hospitalizations are not avoided
with either policy.
Sensitivity analyses
The screening and treatment model can be easily used for sensitivity analyses or for applica-
tions in other settings (all unit costs would need adjustment for other countries). We first con-
sider 5 initial scenarios (denoted as SA1-SA5) beyond the base case, and key results are
summarized in Table 6. SA1 addresses better provider adherence with requesting the test when
indicated in provider-initiated screening (from 40% to 80%), which only affects provider-







Number screened 9,500 1,536 7,964
Total cost of screening (2015 USD) $47,044 $9,508 $37,536
Total cost of treatment (2015 USD) $209,399 $264,564 -$55,165
Total cost of screening + treatment (2015 USD) $256,443 $274,072 -$17,629
Total number of patients known to survive (from treatment model plus those who survive but
are missed and do not enter treatment model)
148 118 30
Total years of life saved from surviving patients 3,189 2,542 647
Cost per additional life year saved (RP compared to PI, USD) -$27.25
doi:10.1371/journal.pone.0158986.t004
Table 5. Disaggregated costs (2015 USD) and quantity of fluconazole tablets (200mg) per 1000,000 CD4 tests.
Reflex Policy (RP) Provider-Initiated Policy (PIP Diff (RP-PIP)
Tablets of fluconazole for preemptive treatment 40,967.94 11,039.78 29,928
Tablets of fluconazole for maintenance treatment 38,893.65 50,086.39 -11,193
Tablets of fluconazole total 79,861.59 61,126.17 18,735
Cost of preemptive fluconazole treatment 2,312.75 623.23 1,690
Cost of in-patient hospitalization 204,890.77 261,113.30 -56,223
Cost of maintenance fluconazole treatment 2,195.65 2,827.52 -632
In-patient costs as share of total costs (treatment + screening) 0.80 0.95
doi:10.1371/journal.pone.0158986.t005
Cost Effectiveness of Reflex and Provider-Initiated CrAg Screening
PLOS ONE | DOI:10.1371/journal.pone.0158986 July 8, 2016 18 / 23
initiated results; SA2 includes better patient adherence with returning for CD4 results (from
60% to 80% for reflex screening; and 52% to 64% for provider initiated). Reflex screening con-
tinues to dominate provider-initiated screening for both scenarios. The same results hold with
higher incident CrAg prevalence (e.g., 3% to 6%). In addition, even if a large proportion of sur-
viving CM patients has long-term impairment, the reflex screening generates more health out-
comes compared to the provider-initiated screening.
As noted in Table 6, the base case model assumes that 90% of incident CrAg positive
patients who are CSF negative at the time of screening develop CM if not initiated on ART
quickly (and 66% will develop CM if initiated on ART). In Table 6, scenarios SA3-5 show how
results change if substantially fewer incident CrAg positive (but CSF negative) individuals
progress to CM (a 50% reduction in both parameters). If a large proportion of these individuals
never develop CM, reflex screening compared to provider-initiated screening incurs more
screening costs but does not save on hospital costs because a large proportion of patients
missed by provider-initiated screening never develop CM. As a result, reflex screening does not
dominate provider-initiated screening, but the cost per additional life year saved is modest
(<$125). If, in addition, a large proportion of surviving CM patients has long-term
impairment, the cost per additional life year saved would increase (e.g.,<$250 with a large pro-
portion patients with serious chronic impairment).
Discussion and Conclusion
Compared to no screening, previous studies have shown that CrAg screening prior to the initi-
ation of ART for patients with baseline CD4 counts< 100 cells/μl is a relatively low cost or
cost-saving policy that also saves lives (11,12). This will remain true as long as a baseline CD4
count continues to be required prior to the initiation of ART, even if in the future, CD4 thresh-
olds disappear as an eligibility criterion for ART initiation.
The question addressed in this analysis is: how best to organize a screening program in a
given setting? The model developed for this analysis and the results reported in Tables 4 and 5,
along with additional sensitivity analyses reported in Table 6, suggest that reflex screening
Table 6. Sensitivity analyses (all cost in 2015 USD, per 100,000 CD4 tests)a.
Base case SA1 SA2 SA3 SA4 SA5
Percentage screened as CrAg positive 0.03
Provider adherence: Percentage of indicated tests requested with provider-initiated screening 0.40 0.80 0.80 0.80 0.80
Patient adherence: Percentage of patients return for CD4 results 0.60 0.80 0.80
Proportion CSF negative that develops CM if not initiated on ART 0.90 0.45 0.45 0.45
Proportion of CSF negative that develops CM if initiated on ART 0.66 0.33 0.33 0.33
Outcomes: Reflex compared to provider-initiated strategy (only compare numbers in the same
column)
Additional number of patients screened 7,964 6,428 5,404 7,964 6,428 5,404
Additional cost of screening (2015 USD) 37,536 28,028 21,690 37,536 28,028 21,690
Additional cost of treatment (2015 USD) -55,165 -35,358 -46,654 20,960 12,957 17,521
Additional cost of screening + treatment (2015 USD) -17,629 -7,330 -24,964 58,496 40,986 39,211
Additional patients known to survive 30 19 25 24 15 20
Additional years of life saved 647 414 547 522 332 441
Additional cost (2015 USD) per additional year of life saved (reflex compared to provider
initiated)
-27 -18 -46 112 123 89
a Empty cell means the number is identical to the base case assumption.
doi:10.1371/journal.pone.0158986.t006
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compared to provider-initiated screening is a relatively low cost or perhaps cost saving policy
that also saves lives.
As with any policy, efficient operational implementation is critical to achieving program tar-
gets. In particular, the important first step is to support patients to know their HIV status and
present for care when their CD4 count is still well above 100 cells/μL. The second key step is to
get patients to return for CD4 results relatively quickly. In South Africa, patients are typically
counseled to return in one week, which if adhered to, provides a good opportunity for CrAg-
positive patients to benefit from early treatment. Given that NHLS typically completes CD4
tests within 48 hours, opportunities to shorten the return-for-CD4 results period could be eval-
uated further.
Third, screening and provision of preemptive fluconazole treatment must be simultaneously
implemented. While a relatively small number of NHLS laboratories provide the bulk of CD4
tests completed in the country, thousands of Primary Health Centers (PHCs) initiate patients
on ART. Based on estimates of 200 mg fluconazole tablets needed per 100,000 CD4 tests in
Table 5, with 3.9 million CD4 count tests completed in NHLS laboratories in 2014, approxi-
mately 3.2 million tablets need to be procured and managed through supply chains to ensure
adequate stocks over time in these thousands of PHCs.
As with most modeling analyses, limitations follow from the need to develop model param-
eters based on data from several sources (and rough estimates when data are especially lack-
ing). As much as possible, parameters for this analysis were generated from a recent evaluation
of CrAg screening programs in South Africa [19]. As shown with the sensitivity analyses in
Table 6, however, changing key parameters related to CrAg prevalence, patients returning for
CD4 results, and providers requesting CrAg tests, does affect the costs and magnitude of out-
comes achieved with both screening strategies. Reflex screening generally dominates provider-
initiated screening or has a low incremental cost-effectiveness ratio as long as a large share of
incident CrAg positive patients develops CM in the absence of anti-fungal treatment. When a
small share of incident CrAg positive patients develop CM in the absence of anti-fungal treat-
ment (see Table 6, SA3-5), reflex screening costs more overall (screening plus treatment) but
continues to have a low incremental cost-effectiveness ratio (< $125 per life year saved).
Besides the reflex and provider-initiated CrAg screening policies currently included in
South Africa’s HIV guidelines, additional strategies have been discussed or may be relevant in
the future. First, for example, point-of-care (POC) CrAg screening as part of a provider-initi-
ated approach, using a lateral flow assay (LFA) method when a patient returns for CD4 results,
is possible. However, unless paired with a POC CD4 test, this approach does not provide CrAg
results to patients any sooner than the reflex policy, but would eliminate the need for a third
return visit under a provider-initiated policy. While the CrAg LFA can be performed relatively
easily as a POC test, a large scale program of training, quality control, supply chain manage-
ment, and data systems would need to be developed for POC CrAg screening to be imple-
mented across thousands of PHCs with equivalent quality to current lab-based CrAg screening
[30]. The additional costs from reflex lab screening of patients already on ART and/or with a
history of CM are likely to be relatively minor compared to the costs of developing a national
POC CrAg screening program.
Second, in the future quantitative CrAg tests, reporting a CrAg titer to better differentiate dis-
ease status, may help target those who should receive preemptive treatment with fluconazole and
who should be admitted and treated with amphotericin. While beyond the scope of the current
paper, the existing model could be adapted to such strategies for assessing costs and effectiveness.
And third, all patients testing positive for HIV could be prescribed an initial short-course of
fluconazole, or perhaps only patients clinically suspected to have a low CD4 cell count based
onWHO staging or some other criteria, while awaiting CD4 results. When these patients
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return for their CD4 result and CrAg result (if CD4< 100 cells/μl and with reflex screening),
those testing CrAg negative would stop fluconazole treatment and immediately initiate ART,
while those CrAg positive would continue with preemptive treatment prior to initiating ART.
Future research is needed to evaluate the health risks and benefits of such an approach. How-
ever, the logic of this third approach becomes more relevant if CD4 test results are not required
prior to the initiation of ART as is the case for countries considering “test and treat” policies.
CrAg screening prior to the initiation of ART is a relatively low cost or potentially cost sav-
ing policy as long as a baseline CD4 count continues to be included in national guidelines prior
to the initiation of ART. Even if all HIV patients are eligible for ART, regardless of CD4 counts,
the question remains if a baseline CD4 count will be required prior to initiation of ART or not.
If guidelines under new test-and-treat policies still include baseline CD4 counts and other
laboratory tests prior to initiation of ART, then a reflex CrAg screening strategy imposes no
additional delays on ART initiation for the vast majority of patients. For the relatively few total
HIV-infected patients with low CD4 counts who are CrAg positive, appropriate treatment
(preemptive fluconazole or hospitalization) can still begin prior to initiation of ART.
However, CrAg screening prior to the initiation of ART becomes more complicated if poli-
cies change to same-day ART initiation after an HIV diagnosis (or at initial presentation to a
PHC if tested in a mobile testing program). If an immediate test-and-treat approach is imple-
mented as a national policy, CrAg screening before initiation of ART would require both pro-
vider-initiated POC CD4 and CrAg testing. Alternatively, CrAg screening after initiation of
ART (perhaps implemented discussed above) would need to be evaluated further.
To date, all analyses of CrAg screening have assumed the presence of CD4 results to target
screening. In the absence of such information, future research is needed to compare non-CD4
based strategies for screening, as well as the benefits of CrAg screening for the small proportion
of newly-diagnosed HIV-infected patients with low CD4 counts who are incident CrAg posi-
tive to the possible costs of delaying ART initiation for the vast majority of all patients (those
with CD4 counts> 100 cells/μl and those with low CD4 counts who are CrAg negative).
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